Try our Advanced Search for more refined results
Life Sciences
-
April 27, 2026
4 Firms Build Astorg's $1.1B Microbiology Biz Buy
Life sciences company Thermo Fisher Scientific Inc. on Monday announced plans to sell its microbiology business to European private equity firm Astorg in an over $1.1 billion deal steered by four law firms.
-
April 27, 2026
3rd Circ. Panel Once Again Backs Talc Co. Whittaker's Ch. 11
The Third Circuit on Monday upheld its decision that Whittaker Clark & Daniels' was authorized to file for Chapter 11 and certain claims against the defunct talc supplier's corporate successor belong to the debtor, not personal injury claimants.
-
April 27, 2026
Bioscience Co. Allegedly Hid Volatility Risks From Investors
A company purportedly focused on using traditional Chinese medicine to treat conditions including autism spectrum disorder faces a proposed investor class action alleging it downplayed the risk it would be probed in connection with unusual volatility affecting the market for its shares.
-
April 27, 2026
McCarter & English Plans New Waterfront Home In Boston
New Jersey-based McCarter & English LLP has chosen a new home for its Boston office, opting for a location in the middle of the city's downtown waterfront district, the firm has announced.
-
April 27, 2026
Catching Up With Delaware's Chancery Court
The Delaware Chancery Court this past week tackled a fresh mix of deal litigation, procedural disputes and fiduciary duty claims, with several rulings and filings underscoring the court's continued focus on contractual precision, forum enforcement and the limits of stockholder challenges.
-
April 27, 2026
What To Watch As Justices Take On 'Skinny Label' Case
The U.S. Supreme Court will hear arguments Wednesday on whether to permit a patent suit over a generic heart drug using a so-called skinny label, a case with ramifications for the drug industry that could shape patent disputes more broadly and other legal areas. Here's what to watch for.
-
April 27, 2026
Ropes & Gray, Cooley Lead Lilly's $2.3B Cancer Drug Buy
Eli Lilly and Co. said Monday it will acquire privately held Ajax Therapeutics in a deal worth up to $2.3 billion, as the drugmaker looks to expand its pipeline of treatments for blood cancers.
-
April 27, 2026
US, Indian Firms Guide $11.75B Sun Pharma-Organon Deal
Indian pharmaceutical giant Sun Pharmaceutical Industries Ltd. has agreed to acquire New Jersey-based Organon & Co. in an all-cash deal valued at $11.75 billion, with each side of the transaction having representation from one U.S. and one Indian law firm.
-
April 24, 2026
Up Last At High Court: TPS, Geofence, Skinny Labels
The U.S. Supreme Court will close out its oral argument portion of the 2025 October term by hearing a panoply of disputes over the constitutionality of geofence warrants, the existence of aiding and abetting torture claims, and the rescission of temporary protected status for hundreds of thousands of immigrants.
-
April 24, 2026
Natera Tells Justices CareDx Made Up Circ. Split In Petition
Natera asked the U.S. Supreme Court to reject a petition from rival CareDx asking it to review a Third Circuit decision that erased a $45 million jury verdict stemming from CareDx's false advertising claims, saying Friday the circuit split that CareDx claims exists is "imagined."
-
April 24, 2026
NY Court Pauses $100M Saudi Arabia Pharma Award Suit
A New York federal judge has paused litigation filed by a Qatari pharmaceutical distributor and its chairman aimed at enforcing a nearly $100 million arbitral award against Saudi Arabia while a hearing is conducted in the kingdom's set-aside petition in England next week.
-
April 24, 2026
What's At Stake As High Court Hears Roundup Appeal
With a $7.25 billion deal potentially at stake, Monsanto heads to the U.S. Supreme Court on Monday in its closely watched appeal of a $1.25 million jury verdict awarded to a Missouri man who claimed that Roundup weed killer caused his cancer.
-
April 24, 2026
Danaher Execs Face Investor Suit Over Post-COVID Outlook
Danaher Corp. executives are facing a proposed securities class action in Delaware federal court alleging they profited while misleading stockholders about the slowing sales of its diagnostics and bioprocessing products.
-
April 24, 2026
Merck's $6.7B Terns Deal Clears Regulatory Hurdle
Merck has cleared a key regulatory hurdle in its plan to acquire clinical stage oncology company Terns Pharmaceuticals Inc. for $6.7 billion, the pharmaceutical giant said Friday.
-
April 24, 2026
Pfizer, Dexcel Drop Heart Drug Case Before Bench Trial
Pfizer and Israeli generic-drug maker Dexcel on Friday agreed to drop a case Pfizer brought to block Dexcel from creating a generic version of the heart medication Vyndamax.
-
April 24, 2026
Biotechs Clash Over Cancer Drug Discovery In Chancery
AnaptysBio and Tesaro, alongside Tesaro parent GlaxoSmithKline LLC, sparred Friday in the Delaware Chancery Court over the scope of discovery in the biotechnology firms' contract fight regarding cancer drug Jemperli, with each side accusing the other of trying to tilt the evidentiary record ahead of a fast-approaching trial in July.
-
April 24, 2026
Taxation With Representation: Gibson Dunn, Paul Weiss
In this week's Taxation With Representation, Elon Musk's SpaceX strikes a deal with Cursor that could lead to an acquisition of the artificial intelligence startup, building products distributor QXO Inc. buys TopBuild Corp., and Eli Lilly & Co. acquires clinical-stage biotechnology company Kelonia Therapeutics.
-
April 23, 2026
Latest Squires Order Grants 5 IPRs, Denies 4 On The Merits
U.S. Patent and Trademark Office Director John Squires granted five America Invents Act patent challenges and denied four others in his latest bulk order making institution decisions with little commentary.
-
April 23, 2026
Full Fed. Circ. Urged To Rethink Corcept Patent Loss
Corcept Therapeutics Inc. wants the Federal Circuit to rethink a panel's refusal to revive its suit accusing Teva Pharmaceuticals USA Inc. of patent infringement over its production of a generic version of the drug Korlym, saying the panel improperly relied on a ruling from a 2022 case.
-
April 23, 2026
FTC Cuts Deal To End Anesthesia Group Rollup Case
The Federal Trade Commission reached an agreement Thursday to settle its case accusing U.S. Anesthesia Partners Inc. of monopolizing the Texas anesthesia services market by purchasing most of the competing anesthesia practices in the state.
-
April 23, 2026
Pa. County Joins Insulin-Pricing Suit Blitz Against CVS, PBMs
Chester County, Pennsylvania, filed its own suit in a sprawling multidistrict litigation against CVS and multiple pharmacy benefit managers and drug companies, claiming the entities worked together to inflate the price of insulin.
-
April 23, 2026
Kirkland To Add Tenn. SG Behind Skrmetti Supreme Court Win
The Tennessee solicitor general, who successfully defended the state's ban on some gender-affirming care for minors before the U.S. Supreme Court, will join the Nashville office of Kirkland & Ellis, the firm announced Thursday.
-
April 23, 2026
Firm Seeking Philly Zantac Judge's Recusal Appeals Refusal
A plaintiff represented by Keller Postman LLC has asked the Pennsylvania Superior Court to weigh in on a Philadelphia judge's refusal to recuse himself from overseeing mass tort litigation against GlaxoSmithKline over Zantac's alleged cancer risks.
-
April 23, 2026
ITC Investigating Chinese Biopharma Chemicals Over Pricing
The U.S. International Trade Commission is looking into whether Chinese imports of two chemicals used in biopharma manufacturing that are allegedly being sold at unfair prices are harming U.S. domestic industry, it said in a notice published Thursday.
-
April 23, 2026
DOJ Says Medical Pot Shift Shouldn't Affect Gun Rights Case
Despite an order from the U.S. Department of Justice loosening federal restrictions on medical marijuana, the Trump administration signaled Thursday that it does not intend for the changes to cannabis regulation to apply retroactively.
Editor's Picks
-
Supreme Court Will Tackle Patent Enablement In Amgen Case
The U.S. Supreme Court on Friday agreed to review Section 112 of the Patent Act for the second time in the law's history, accepting Amgen's request to consider how much a patent must disclose in order to meet enablement requirements.
-
A Circuit-By-Circuit Guide To FCA Suits After High Court Snub
The U.S. Supreme Court's refusal to resolve one of the False Claims Act's most consequential controversies leaves circuit courts deeply divided over whistleblower pleading obligations in ways that will reverberate nationwide, attorneys say. Here, Law360 explores each circuit's approach and scenarios that might finally trigger high court intervention.
-
Inside The Collapse Of A Pioneering Opioid Case For DOJ
The U.S. Department of Justice launched a "terribly flawed" criminal case against a drug distributor and several individuals amid pressure to alleviate Appalachia's opioid crisis, and a newly confirmed U.S. attorney displayed "courage and guts" by ending the case last month, defense counsel told Law360 in an expansive interview.
Expert Analysis
-
How Food, Beverage Claims May Preview Cosmetic Litigation
Class action litigation targeting cosmetics and personal care products is accelerating, with a playbook that comes from the food and beverage industry — and the defenses that succeeded, and failed, in past class actions offer a critical road map for beauty and personal care brands, say attorneys at Crowell.
-
Court's HRSA Policy Reversal Leaves 340B Rules Murky
A D.C. federal court's recent decision in Premier v. U.S. Department of Health limits the Health Resources and Services Administration's ability to enforce long-standing Section 340B interpretations through subregulatory guidance, leaving open core statutory questions about purchasing models, inventory classification and program oversight, says Martha Cramer at Hooper Lundy.
-
Series
Officiating Football Makes Me A Better Lawyer
Though they may seem to have little in common, officiating football has sharpened many of the same skills that define effective lawyering in management-side labor and employment: preparation, judgment, composure, credibility and ability to make difficult decisions in real time, says Josh Nadreau at Fisher Phillips.
-
Fresenius Ruling May Shift Anti-Kickback Enforcement
The Ninth Circuit's recent decision in Fresenius v. Bonta suggests that businesses have a First Amendment right to donate to certain charities, even if those donations are motivated by economic self-interest, potentially calling into question years of Anti-Kickback Statute proceedings against pharmaceutical manufacturers for making similar donations, says Jonah Knobler at Patterson Belknap.
-
Written Consent Ruling May Signal Change For Telemarketing
The Fifth Circuit's ruling in Bradford v. Sovereign Pest Control is a takedown of the Federal Communications Commission's prior express written consent regulation, and because Loper Bright empowers courts to disregard agency interpretations, Telephone Consumer Protection Act litigants now have an opportunity to challenge previously settled FCC regulations, orders and interpretations, say attorneys at Manatt.
-
Series
Law School's Missed Lessons: How To Draft Pleadings
Most law school graduates step into their first jobs without ever having drafted a complaint, answer, motion or other type of pleading, but that gap can be closed by understanding the strategy embedded in every filing, writing with clarity and purpose, and seeking feedback at every step, says Eric Yakaitis at Haug Barron.
-
At The Fed. Circ., Means-Plus-Function Is Not Quite Dead
Recent Federal Circuit opinions confirm that means-plus-function claims continue to be drafted, issued, litigated and even infringed — but minding the restrictions imposed over the years by courts and statute requires three steps, says Jay Yates at Patterson & Sheridan.
-
E-Discovery Quarterly: Recent Rulings On ESI Control
Several recent federal court decisions have perpetuated a split over what constitutes “control” of electronically stored information — with judges divided on whether the standard should turn on a party's legal right or practical ability to obtain the information, say attorneys at Sidley.
-
Opinion
USPTO Should Let Inventors Valuate Patents In Prosecution
By building patent valuation into the application process, rather than waiting until potential litigation years down the line, the U.S. Patent and Trademark Office would streamline the process for inventors protecting and enforcing their patents, says John Powers at Powers IP.
-
2 Discovery Rulings Break With Heppner On AI Privilege Issue
While a New York federal court’s recent ruling in U.S. v. Heppner suggests that some litigants’ communications with AI tools are discoverable, two other recent federal court decisions demonstrate that such interactions generally qualify for work-product protection under the Federal Rules of Civil Procedure, says Joshua Dunn at Brown Rudnick.
-
Series
Isshin-Ryu Karate Makes Me A Better Lawyer
My involvement in martial arts, specifically Isshin-ryu, which has principles rooted in the eight codes of karate, has been one of the most foundational in the development of my personality, and particularly my approach to challenges — including in my practice of law, says Kaitlyn Stone at Barnes & Thornburg.
-
Microplastics On Water Contaminant List Could Spur Claims
The U.S. Environmental Protection Agency's proposal to include microplastics in its draft sixth Contaminant Candidate List under the Safe Drinking Water Act could influence consumer fraud claims and enforcement by state attorneys general, as well as claims against manufacturers from entities facing regulatory compliance costs, says Arie Feltman-Frank at Jenner & Block.
-
USPTO's AI Search Pilot May Reshape Patent Filing Strategy
The U.S. Patent and Trademark Office's new artificial intelligence search pilot aims to introduce earlier visibility into the prior art landscape, potentially influencing patent filing considerations and shifting the role of counsel to an earlier stage of the prosecution process, say attorneys at Foley & Lardner.
-
Peptide Policy Is Shifting Toward Sanctioned Compounding
The policy landscape for peptides is undergoing a significant shift under the Trump administration, moving toward a complex system of verified compounding and complementary enforcement that will likely bring peptides firmly back into the sphere of legitimate consumer products, say attorneys at Sheppard.
-
Keys To Building Defensible Psychedelic Therapy Programs
Given the rapidly evolving legal environment for psychedelic therapies and heightened liability and compliance risks facing providers, meticulous documentation, robust risk management protocols, and proactive engagement with professional organizations and insurers are essential strategies, say Kimberly Chew at Husch Blackwell and L. Alison McInnes at Mindful Health Solutions.